 |
 |
Many screening
groups traditionally subscribe to the “workstation”
approach for assay assembly – using
standalone, automated dispensers, incubators
and readers with the assay plates being
transferred manually between workstations.
However, as the numbers of compounds and
targets available substantially increase,
the limitations of the equipment becomes
apparent. Furthermore, the logistics of
manually scheduling and tracking processes
can lead to data inconsistency and quality
issues. |
| |
Asset
has been developed as a fully integrated,
high performance automation platform offering
the unique combination of flexibility, assay
quality and throughput: |
| |
- Screens 250,000 compounds in 8 hours,
to meet peak demands and complete high
priority screens quickly. Rapid and
simple changeover between runs and assay
types and minimal operator involvement
- Compatible with all existing assay
technologies, including those using
coated wells and live cells, accommodating
96, 384 and 1536-well plate formats
- Demonstrates exceptional data quality
(Z’) in screening studies
- Asset is operational at major pharmaceutical
sites, including GlaxoSmithKline,
AstraZeneca
and Wyeth,
routinely screening large compound libraries
against a wide range of assay types
|
| |
For more information
visit, SMS
Systems -Asset System Overview |
| 
|
| |
Many compound management
centres are now tasked with extending their
existing plate preparation facility to deliver
assay-ready plates containing nanolitre
quantities per well, to achieve goals in
assay miniaturisation, reduced consumption
of compound stock, and reduced exposure
of the assay to DMSO solvent. |
| |
BasePlateXR
can meet this need in two different ways: |
| |
- It can be furnished with a Genomic
Solutions Hummingbird™ low-volume
pipette head in place of one of the
standard air displacement pipette blocks,
allowing block replication of fixed
low volumes working in tandem with a
conventional head for diluent addition
and larger volume transfers
- Alternatively it can incorporate one
or more acoustic transfer devices such
as the Labcyte Echo dispenser. In this
case BasePlateXR can also incorporate
centrifuging to prepare the source plates
|
| |
In both options the established
unique benefits of BasePlateXR are extended
to the production of low volume output plates.
PlateSafes, robotically sealable canisters
with optional sacrificial plates and gas
purging, protect the newly created plates
and permit plates to be created without
having to seal each plate. This avoids distortion,
saves time, and permits direct transfer
to an assay platform. Where preferred, BasePlateXR
can apply seals as well as labelling output
plates. |
| |
- A number of major life science companies,
including AstraZeneca,
Aventis, Evotec OAI, Johnson & Johnson
and Pfizer,
have chosen BasePlateXR to support their
plate preparation requirements
|
| |
For more information
visit, SMS
Systems - BasePlate XR System Overview |
| |
For
more information on high throughput screening |
| |
Get more
details on TAP's
SMS Systems |
| |
Discuss
your requirements with Ian
Ransome, Sales Director |
| <<
Back to key applications in Sample Management
& Screening |
|
